Docetaxel-based chemotherapy trials in androgen-independent prostate cancer: first demonstration of a survival benefit

Affiliations

¹ Department of Medicine, Division of Medical Oncology, College of Physicians and Surgeons, Columbia-Presbyterian Medical Center, 161 Fort Washington Avenue, New York, NY 10032, USA. dpp5@columbia.edu

Comment

Daniel P Petrylak. Curr Oncol Rep. 2005 May.

. 2005 May;7(3):205-6.

doi: 10.1007/s11912-005-0074-1.

¹ Department of Medicine, Division of Medical Oncology, College of Physicians and Surgeons, Columbia-Presbyterian Medical Center, 161 Fort Washington Avenue, New York, NY 10032, USA. dpp5@columbia.edu

No abstract available

Comment on

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA; TAX 327 Investigators. Tannock IF, et al. N Engl J Med. 2004 Oct 7;351(15):1502-12. doi: 10.1056/NEJMoa040720. N Engl J Med. 2004. PMID: 15470213 Clinical Trial.
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Petrylak DP, et al. N Engl J Med. 2004 Oct 7;351(15):1513-20. doi: 10.1056/NEJMoa041318. N Engl J Med. 2004. PMID: 15470214 Clinical Trial.